|
| On-Demand Webinar: Clinical Adjudication Survey Results Revealed In a recent survey, 89% of clinical adjudication users agreed clinical adjudication provides value to clinical trials. Why? Because using unbiased experts to evaluate a drug or device against predetermined criteria helps determine patient safety and clinical efficacy. Join two experts for a discussion of these and other survey results to understand how they could impact your studies. View Now. |
Pfizer carries pandemic momentum into 2022, scoring another huge Paxlovid deal with the US Ex-Theranos CEO Elizabeth Holmes found guilty on four of 11 counts of fraud 2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs CMS pulls Trump-era Most Favored Nation drug price model Co-Diagnostics completes two-pronged acquisition to begin rolling out at-home COVID testing device Avrobio shares plummet as Fabry program axed, new trial starts slated for 2023 Biogen, Ionis see no need to change the formula for Spinraza successor Pfizer, GSK and Teva lead 2022's round of January drug price hikes: GoodRx HCA Healthcare scoops up MD Now Urgent Care's 59 Florida clinics to support state-wide investments Applied pumps brakes on FDA application after request for more data Desktop DNA printer maker DNA Script adds to its 9-digit VC round Walmart Health exec Marcus Osborne leaves the retailer amid ongoing leadership changes Novavax gathers its COVID-19 vaccine data for long-delayed FDA filing CMS: Health workers in 25 states and D.C. must be fully vaccinated by Feb. 28 Featured Story | By Fraiser Kansteiner The U.S. is doubling its order of Pfizer's COVID-19 antiviral Paxlovid, buying a total supply of 20 million treatment courses so far. The move likely means Pfizer's pandemic revenue forecast will need to be scaled up, again. read more |
| |
|---|
|
|
| Webinar: A Collaborative Approach to Complex Chemistry Wednesday, January 12, 2022 | 11am ET / 8am PT Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now. |
Top Stories By Andrea Park In a decision that may serve as yet another warning to other tech startups that have raked in millions of dollars in venture capital based largely on promises, rather than actual results, former Theranos CEO Elizabeth Holmes was found guilty on four counts of defrauding investors. read more By Eric Sagonowsky Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, the 2021 batch of new drug approvals clearly demonstrates that the sector has learned how to operate in a pandemic. read more By Robert King CMS has pulled a controversial Trump-era model that would have tied Medicare Part B drug reimbursements to prices paid by countries overseas. read more By Andrea Park With barely a week left in 2021, Co-Diagnostics got a head start on its plans for the new year by announcing and, within just a few days, promptly closing a pair of acquisitions. read more By Kyle LaHucik Avrobio already trimmed expectations for its Fabry disease gene therapy in May because of Sanofi's Fabrazyme approval, and now the biotech is axing it all together. read more By Annalee Armstrong When it comes to spinal muscular atrophy, Biogen and Ionis are two peas in a pod. The companies have signed yet another licensing deal to develop a next-generation treatment for the genetic disorder after the success of Spinraza. read more By Fraiser Kansteiner One thing many pharma companies declined to include in their New Year's resolutions? Lowering the prices of expensive brand name drugs. Within the first few days of the year, drugmakers have raised U.S. list prices on more than 400 meds, GoodRx reports. read more By Dave Muoio The purchase, which closed in 2021, brings the chain to a total of more than 170 urgent care clinics nationwide. Other terms of the deal were not disclosed. read more By Kyle LaHucik Applied Therapeutics is pumping the brakes on requesting FDA approval for its first drug after the agency requested clinical outcomes data on the treatment's impact in a rare metabolic disease. read more By Conor Hale DNA Script tacked on an additional $35 million for a grand total of $200 million to help promote the launch of its new systems. read more By Heather Landi Marcus Osborne, who played a key role in Walmart's push into healthcare and headed up its medical clinics, has left the retail giant. Osborne, who served as senior vice president of Walmart Health, announced his departure in a LinkedIn post on January 1. read more By Fraiser Kansteiner Novavax spent much of 2021 working to file its COVID-19 vaccine with U.S. regulators but falling short of its own deadlines. As the year came to a close, the company celebrated the fact that it was nearly there. read more By Robert King CMS is now requiring states that are not affected by a legal stay to fully vaccinate all staff by Feb. 28, 2022, or risk losing participation in Medicare and Medicaid. read more |
